IRA THREATENS CURES FOR PATIENTS WITH BLOOD CLOTS

Study Shows Government-Mandated Drug Pricing Policies Decimate Development of Drugs Treating Blood Clots

A new study by research firm Vital Transformation estimates that there would be hundreds of lost therapies, including those for patients battling blood clots and other artery issues, if Congress expands new aggressive governmentmandated drug pricing policies.

LOST THERAPIES

 70% of all currently available medicines – treatments
Americans rely on every day – would likely never have been created, including nearly a dozen that help with blood clots and related cardiology and circulatory issues.




LOST INNOVATION

237 fewer medicines will be FDA-approved over the next decade, especially in areas where we are desperately seeking cures – like blood clots.

"PILL PENALTY" THREATENS DEVELOPMENT OF BLOOD-CLOTTING TREATMENTS

The new IRA law discourages the development of medicines that come in pill or tablet form, often referred to as "small molecule medicines." These include blood thinners and anti-thrombotic drugs to help inhibit the formation of clots, and antiplatelet agents and thrombolytics to break down existing clots.¹



IRA THREATENS CURES FOR PATIENTS WITH BLOOD CLOTS



IRA THREATENS BLOOD CLOT PREVENTION AND TREATMENTS FOR PATIENTS OF ALL BACKGROUNDS

Blood clots represent some of the most common medical conditions, but the IRA threatens to limit treatment options for patients from all walks of life. Blood clots are preventable and treatable, according to the Centers for Disease Control and Prevention, but six of the 10 drugs subject to the first round of Medicare price setting target the cardiovascular and circulatory systems - including two specifically for blood clots and artery diseases. Any person of any age can be at risk or develop blood clots, which affect an estimated 900,000 Americans each year and result in nearly 100,000 deaths.² The IRA will discourage companies from researching new treatments and new indications for their existing drugs that could help more people avoid the same outlook.

WHAT THEY'RE SAYING ABOUT INVESTMENTS

"I do expect that we will cancel some programs, whether that is, you know, a full-on indication for an existing medicine or a new medicine."

- Giovanni Caforio, CEO of Bristol Myers Squibb³

"The IRA's pricing and provisions will constrain medical innovation, limit patient access and choice, and negatively impact the overall quality of patient care."

- Johnson & Johnson statement⁴



LEARN MORE

The new study issued by We Work For Health (WWFH) and Vital Transformation modeled the impacts on industry revenues, jobs and future research and development investments. For the full study, please visit <u>We Work For Health</u>.

- 1. Fogoros, R. <u>How Blood Clots Are Treated</u>. Very Well Health. June 5, 2023.
- 2. <u>Are You At Risk For Clots?</u> Centers for Disease Control and Prevention.
- 3. Smyth, J. Bristol Myers Squibb warns US price reforms will dent drug development. Financial Times. Nov. 22, 2022.
- 4. Protecting the Healthcare Innovation Ecosystem. Johnson & Johnson. July 18, 2023.